Rate My Professor Hugo Albrecht

Dr. Hugo Albrecht serves as Senior Lecturer in Pharmaceutical Science at Adelaide University, within the School of Pharmacy and Biomedical Sciences, College of Health. He earned his PhD at the Ludwig Institute for Cancer Research, Lausanne Branch, Switzerland. Albrecht brings over 20 years of expertise in preclinical pharmaceutical development from both commercial and academic settings in Europe and the United States, where he has led more than 20 major drug discovery projects. His academic career emphasizes innovative approaches to drug development, including the creation of biochemical and cell-based assay systems, animal models for compound testing, and the discovery of novel kinase inhibitors targeted at cancer therapies. Albrecht also designs functional nanoparticles for precise drug delivery into tumor cells, contributing to the Centre for Pharmaceutical Innovation as a steering committee member.

Albrecht's research spans cancer, immunology, and neuroscience, with a focus on advancing targeted nanomedicines and kinase inhibitors. Key publications include 'Protease-Activated Receptor F2R Is a Potential Target for New Diagnostic/Prognostic and Treatment Applications for Patients with Ovarian Cancer' (International Journal of Molecular Sciences, 2025), 'Targeting F2R/PAR1 with ligand decorated lipid nanocarriers for enhanced drug delivery into ovarian cancer cells' (Frontiers in Drug Delivery, 2026), 'Unveiling G-protein coupled receptors as potential targets for ovarian cancer nanomedicines: from RNA sequencing data analysis to in vitro validation' (Journal of Ovarian Research, 2024), 'Using GPCRs as Molecular Beacons to Target Ovarian Cancer with Nanomedicines' (Cancers, 2022), 'CDK9: A comprehensive review of its biology, and its role as a potential target for anti-cancer agents' (Frontiers in Oncology, 2021), and 'Position matters: pyridine regioisomers influence secondary structure and micelle morphology in polymer-homopolypeptide micelles' (Biomacromolecules, 2024). These works highlight his impact on developing novel therapeutic strategies for ovarian and other cancers through nanotechnology and molecular targeting.